Comparing a new drug to standard care for HER2-positive advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called JSKN003 against the usual treatments for people with HER2-positive advanced colorectal cancer that has stopped responding to standard chemotherapy. It aims to see if the new drug can help shrink or control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have colorectal cancer that is HER2-positive and has spread or cannot be removed with surgery.
- Your cancer has not responded to treatment with oxaliplatin, 5-FU or capecitabine, and irinotecan.
- You have at least one tumor that can be measured, and it has not been treated with radiation (or if it has, it is growing).
- You are physically active and able to care for yourself, with a performance status of 0 or 1.
- You have adequate organ function and are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (KN026 plus chemotherapy, with or without KN-046) for people with HER2-positive colorectal or bile duct cancer that has spread. The goal is to see if this treatment can help shrink or control the cancer.
This trial is testing a new drug called BL-M07D1 as a possible treatment for advanced colorectal cancer that has HER2-positive tumors. If you've already tried standard chemotherapy and it didn't work, this study compares the new drug to the doctor's chosen standard treatment.
This trial compares a new drug called JSKN003 with the standard combination of pertuzumab, trastuzumab, and docetaxel for people with HER2-positive breast cancer that has spread or returned. It aims to see if JSKN003 works as well as or better than the current standard first-line treatment.
This trial tests a new drug called JSKN003 for people with HER2-positive stomach cancer. It may be used as a first treatment for advanced cancer or before surgery for cancer that can be removed. The goal is to see if the drug helps shrink or control the cancer.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
Hear when a new HER2-positive Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.